Adoptive Macrophage Transfers for Nanoparticle Delivery
用于纳米颗粒递送的过继巨噬细胞转移
基本信息
- 批准号:10688187
- 负责人:
- 金额:$ 34.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAffectAreaAutoimmune DiseasesBehaviorCardiovascular DiseasesCell surfaceCellsClinicalCommunicable DiseasesComplexContrast MediaDiseaseDrug Delivery SystemsGenesGoalsImmuneInfiltrationInflammationInflammatoryKnowledgeLaboratoriesMacrophageMalignant NeoplasmsMeasuresMediatingMedical ImagingModelingMusOutcomePharmaceutical PreparationsPhenotypeResearch PersonnelRoleShapesSiteSpecificityTissuesVaccinesWorkchemokine receptordesigndifferential expressionepigenomicsimprovedmolecular phenotypenanofabricationnanoparticlenanoparticle deliverynext generationphysical propertyrecruitresponsetooltranscriptomics
项目摘要
ABSTRACT
Immune cells will serve as next-generation vehicles to deliver cargo such as bioactive drugs and contrast agents
to inflamed tissues. Due to their abundant expression of chemokine receptors, cells like macrophages have the
capacity to infiltrate inflamed tissues with remarkable specificity. Researchers are exploiting this capability to
direct the transport of attached nanoparticles containing drugs and other cargo to diseased tissues (e.g., from
cancer, infectious diseases, autoimmune disorders, and cardiovascular disease). However, macrophages are
living entities that can change their function in complex and sometimes unexpected ways when loaded with
nanoparticles. Thus, there is a fundamental need to understand the interactions between macrophages and the
nanoparticles they carry. To address this gap in knowledge, my laboratory will investigate two focus areas. First,
we will study how the physical properties of nanoparticles affect macrophage phenotypes. Using nanofabrication,
we will create nanoparticles that vary in size, shape, stiffness, and composition; direct their attachment onto, or
internalization within, macrophages; and measure their responses using epigenomic, transcriptomic, and
molecular phenotyping tools. This focus area will reveal differentially expressed genes that are involved in the
macrophage responses to nanoparticle loadings of various design. In the second focus area, we will study the
principal factors that govern cell-mediated transport of nanoparticles to inflamed tissues. Different macrophage-
nanoparticle complexes will be made and injected into mice harboring different models of inflammation designed
to recruit different subpopulations of immune cells. We will study the role of nanoparticle placement (i.e., onto
the surfaces of cells versus within their interiors) as well as the role of macrophage phenotypes on their transport
efficiency to inflamed tissues. The outcome of this work will be a set of design rules that predict macrophage-
mediated transport of nanoparticles to inflamed tissues. Once established, these rules will be exploited to guide
the design of new types of nanoparticles that interface with macrophages, promote specific phenotypes that are
advantageous for specific treatments, and facilitate improved transport to those diseased sites. Such a capability
will improve clinical efforts to use adoptively transferred macrophages to deliver drugs, vaccines, and contrast
agents for a range of inflammatory diseases.
摘要
免疫细胞将作为下一代运载工具,运送生物活性药物和造影剂等货物
到发炎的组织由于其趋化因子受体的丰富表达,像巨噬细胞这样的细胞具有趋化性。
以显著的特异性渗透发炎组织的能力。研究人员正在利用这种能力,
引导含有药物和其它货物的附着的纳米颗粒运输到患病组织(例如,从
癌症、传染病、自身免疫性疾病和心血管疾病)。然而,巨噬细胞
生物体,可以改变他们的功能,在复杂的,有时意想不到的方式时,加载
纳米粒子因此,了解巨噬细胞和巨噬细胞之间的相互作用是非常必要的。
它们携带的纳米粒子。为了解决这一知识差距,我的实验室将研究两个重点领域。第一、
我们将研究纳米颗粒的物理性质如何影响巨噬细胞表型。使用纳米纤维,
我们将创造出大小、形状、硬度和成分各不相同的纳米颗粒;将它们直接附着在
内化,巨噬细胞内;并使用表观基因组学,转录组学,
分子表型分析工具。这一重点领域将揭示差异表达的基因,参与了
巨噬细胞对各种设计的纳米颗粒负载的响应。在第二个重点领域,我们将研究
控制纳米颗粒向发炎组织的细胞介导运输的主要因素。不同的巨噬细胞-
纳米颗粒复合物将被制成并注射到携带不同炎症模型的小鼠体内,
来募集不同的免疫细胞亚群。我们将研究纳米粒子放置的作用(即,到
细胞表面与其内部)以及巨噬细胞表型在其转运中的作用
对发炎组织的功效。这项工作的成果将是一套设计规则,预测巨噬细胞-
介导的纳米颗粒向发炎组织的转运。一旦建立,这些规则将被用来指导
设计新型的纳米颗粒与巨噬细胞接触,促进特定的表型,
这对于特定治疗是有利的,并且有助于改善向那些患病部位的运输。这种能力
将改善临床工作,使用过继转移的巨噬细胞来递送药物、疫苗和造影剂,
用于一系列炎性疾病的药剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Wyatt Shields IV其他文献
Charles Wyatt Shields IV的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Wyatt Shields IV', 18)}}的其他基金
Adoptive Macrophage Transfers for Nanoparticle Delivery
用于纳米颗粒递送的过继巨噬细胞转移
- 批准号:
10501313 - 财政年份:2022
- 资助金额:
$ 34.4万 - 项目类别:
Adoptive Macrophage Transfers for Nanoparticle Delivery
用于纳米颗粒递送的过继巨噬细胞转移
- 批准号:
10794553 - 财政年份:2022
- 资助金额:
$ 34.4万 - 项目类别:
Acoustofluidic Pipette for Rapid Serodiagnosis of Candida Infection
用于念珠菌感染快速血清诊断的声流控移液器
- 批准号:
10388272 - 财政年份:2021
- 资助金额:
$ 34.4万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 34.4万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 34.4万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 34.4万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 34.4万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 34.4万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 34.4万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 34.4万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 34.4万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 34.4万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 34.4万 - 项目类别:














{{item.name}}会员




